

1 **Improving Diagnostic Precision: Urine Proteomics Identifies Promising Biomarkers for**
2 **Necrotizing Enterocolitis**

3 Stephen Mackay¹, Lauren C. Frazer¹, Grace K. Bailey¹, Claire M. Miller¹, Qingqing Gong², Olivia
4 N. DeWitt², Misty Good^{1*}

5
6 ¹Division of Neonatal-Perinatal Medicine, Department of Pediatrics, University of North Carolina
7 at Chapel Hill, Chapel Hill, NC, 27517

8 ²Division of Newborn Medicine, Department of Pediatrics, Washington University School of
9 Medicine, St. Louis, MO 63110

10
11 ***Correspondence:**

12 Misty Good, MD, MS

13 Division Chief, Neonatal-Perinatal Medicine

14 Department of Pediatrics

15 The University of North Carolina at Chapel Hill

16 101 Manning Drive Campus Box 7596

17 Chapel Hill, NC 27599

18 Office: 984.974.5063, Fax: 984.974.7857

19 Email: mistygood@unc.edu

20

21

22 **Abstract**

23 **Background:** Necrotizing enterocolitis (NEC) is a severe intestinal disease that primarily
24 impacts preterm infants. Current diagnostic tools are inadequate, so urine proteomics was
25 performed for patients with and without NEC to identify putative biomarkers.

26 **Research design and methods:** The abundance of urinary proteins detected using an
27 aptamer-based microarray was compared for infants with NEC ($n=20$) and controls, age-
28 matched ($n=8$) or self-matched ($n=12$). Spearman r correlation and hierarchical cluster analysis
29 were performed. The area under the curve (AUC) was calculated for receiver operator
30 characteristic curves (ROC).

31 **Results:** Ninety-nine proteins differed in NEC vs. controls based on median fold change ($\text{Log}_2 \pm$
32 1.1) and significance ($P < 0.05$). Patterns of abundance were consistent for both types of
33 matching, and samples clustered based on NEC severity. Two panels were built to differentiate
34 between infants with and without NEC. Panel 1 included proteins associated with
35 inflammation/NEC and produced by the intestinal epithelium (REG1B, REG3A, FABP2, DEFA5,
36 AUC 0.90). Panel 2 consisted of proteins with the largest fold change between NEC vs. controls
37 and the highest individual AUC values (REG1B, SSBP1, CRYZL1, ITM2B, IL36B, IL36RN, AUC
38 0.98).

39 **Conclusions:** Urine proteins significantly differ between infants with and without NEC, which
40 supports their potential as future biomarkers.

41

42 **Keywords:** Aptamer-based microarray, Biomarker, Necrotizing enterocolitis, Neonatal Intestine,
43 Preterm, Urine Proteomics.

44

45 **Background**

46 Necrotizing enterocolitis (NEC) is a rapidly progressive intestinal disease that occurs
47 primarily in preterm and low birth weight neonates and has an incidence of ~7% for neonates
48 born at < 32 weeks gestation [1]. The first symptoms of NEC, such as feeding intolerance and
49 abdominal distension, can be difficult to distinguish from other etiologies; however, within hours
50 of disease onset, an infant with NEC can progress to needing emergency surgery or death. The
51 rapidity of this clinical decompensation is why an early and accurate diagnosis of NEC is
52 essential. Currently, NEC is diagnosed using imaging modalities such as abdominal X-rays
53 and/or ultrasound combined with physical exams and laboratory tests, but these tools have
54 inadequate sensitivity and specificity, particularly early in the disease course [2]. Unfortunately,
55 no biomarkers for NEC have been implemented in routine clinical practice, which could improve
56 upon some of the current diagnostic limitations.

57 Identification of biomarkers for NEC has been hindered by a multitude of factors, with the
58 primary barrier being an incomplete understanding of disease pathogenesis. NEC is thought to
59 result from a poorly controlled immune response in the neonatal intestine in the setting of a
60 dysbiotic microbiome. This inflammation leads to intestinal epithelial injury, loss of mucosal
61 barrier integrity, and, ultimately, tissue necrosis [3-6]. The precise factors that induce and
62 exacerbate disease remain an area of active investigation, and that knowledge barrier continues
63 to impede biomarker development.

64 Several potential biomarkers have been identified for NEC, including proteins/peptides
65 [7,8], metabolites [9], and non-coding RNAs [10,11], but reproducibility and validation of the
66 biomarkers in large cohorts have not been conclusive. In addition, some urinary biomarkers for

67 NEC have been identified, such as fatty acid binding protein-2 (FABP2) [12]; however, these
68 markers are not in use clinically, as normalization of urine samples has been problematic [12].
69 Optimally, a biomarker for NEC would identify infants early in the disease process and reliably
70 differentiate between neonates with NEC and other intestinal or systemic inflammatory
71 pathologies. In addition, an ideal biomarker would be validated for use with biological specimens
72 that are readily available and non-invasively acquired, given the difficulties associated with
73 acquiring specimens from medically fragile preterm neonates. To overcome the difficulty in
74 obtaining a large number of infants with NEC at one center, we established the multi-center
75 NEC Biorepository to identify biomarkers of disease [13,14].

76 With improvements in technology, the identification of new biomarkers for NEC is now a
77 distinct possibility. Traditional methods for biomarker identification include quantitative and
78 qualitative analysis of proteins and metabolites using untargeted gas or liquid chromatography
79 coupled with tandem mass spectrometry (LC-MS/MS). Recently, aptamer-based proteomic
80 screens using large, highly selective libraries have been utilized to screen samples for
81 biomarkers in various tissue and biological specimens, including serum, stool, and urine [15-17].
82 Compared to LC-MS/MS, aptamer-based scans are better able to detect small proteins [18],
83 which presents the opportunity to detect new biomarkers for NEC.

84 In this study, we utilized aptamer-based proteomics technology (SomaScan[®]) to
85 measure the relative abundance of over 7000 proteins in the urine of infants with NEC and
86 controls. We identified ninety-nine proteins that differed between the groups and performed a
87 detailed analysis of protein abundance, patterns across samples, disease severity, and
88 diagnostic utility. In addition, we identified two protein panels and a pair of proteins that
89 effectively differentiate between infants with NEC and controls. This study provides the

90 foundation for future work investigating urine biomarkers for NEC in a larger population of
91 preterm infants and provides an advance toward identifying urgently needed biomarkers for this
92 devastating disease.

93 **Methods**

94 *Study design*

95 Samples were prospectively collected from infants admitted to the St. Louis Children's
96 Hospital Neonatal Intensive Care Unit (NICU) in St. Louis, Missouri, USA. Enrollment of infants
97 22 to 42 weeks gestation was conducted according to protocols approved by the Washington
98 University in St. Louis School of Medicine Institutional Review Board (IRB protocol numbers
99 201706182 and 201802101). Infants with major congenital anomalies were excluded. For the
100 current study, we included infants initially enrolled as controls and then subsequently developed
101 NEC (self-matched, $n = 12$). We also analyzed a cohort of age-matched infants ($n = 8$ pairs),
102 which included infants enrolled at the time of NEC diagnosis ($n = 8$) and their age-matched
103 controls ($n = 8$). Infants with urinary tract infections were excluded. The cohort was comprised of
104 infants born between 24 and 36 weeks gestation ($n = 28$) (**Table 1**) and modified Bell's staging
105 was used to categorize NEC severity [19-21].

106

107 *Sample collection*

108 Urine samples were collected by placing sterile gauze in a clean diaper. Urine-saturated
109 gauze was then collected at a routine care time, placed in a 10 mL syringe, and stored at 4°C
110 until processed by laboratory staff 1-2 times per day. Urine was subsequently extracted from the

111 gauze by squeezing the syringe, aliquoted into cryotubes, and stored at -80°C until analysis.

112 Samples with visible stool contamination were discarded.

113

114 *Proteomics assays*

115 *Sample preparation for SomaScan® and ELISA*

116 Frozen urine samples (-80°C) were thawed in a water bath for 15 min at 37°C and mixed
117 by pipetting before combining 216 µL urine with 9 µL of 1 M Tris-HCl to a final concentration of
118 40 mM. The samples, in two 100 µL volumes, were desalted by buffer exchange using a Zeba™
119 7 kDa MWCO Spin column desalting plate (ThermoFisher Scientific, Waltham, MA) according to
120 the manufacturer's guidelines. Desalting plates reached room temp before centrifuging at 1000
121 x g for 2 min to remove the storage buffer. A 250 µL volume of assay buffer was added to the
122 resin beds and centrifuged at 1000 x g for 2 min. This was repeated three times. Protein
123 concentration was determined using a Pierce™ Micro BCA™ protein assay kit (ThermoFisher
124 Scientific, Waltham, MA) according to the manufacturer's instructions.

125

126 *SomaScan® proteomic assay*

127 The differential abundance of proteins in urine samples was measured using an
128 aptamer-based SomaScan® 7,000 protein microarray assay kit v4.1 (SomaLogic®, Boulder, CO,
129 USA) as previously described [22]. Briefly, the microarray screened proteins using "Slow Off-
130 Rate Modified Aptamers" (SOMAmers®) that were selected against protein epitopes using the
131 Systematic Evolution of Ligands by Exponential Enrichment (SELEX) [22]. The scan utilized a

132 resolution of 5 μm and detected Cy3 fluorescence expressed as relative fluorescence units
133 (RFU). Off-scanner raw signal values were calibrated, standardized, and scaled at multiple
134 dilution categories, namely S1 (61% of proteins), S2 (~38.5%), and S3 (0.4%), where S1 targets
135 low abundant proteins, and S3 targets proteins close to saturation. RFU readouts were
136 analyzed using the Agilent Feature Extraction v10.7.3.1 (Agilent Technologies, Santa Clara,
137 CA). Differential abundance was calculated using the SomaScan[®] statistical analysis tool v4.1
138 and fitted as a linear model of the signal data and an empirical analysis by a Bayesian statistical
139 test for group comparisons.

140

141 *ELISA*

142 Proteins selected for ELISA validation included REG1B (EH389RB, ThermoFisher
143 Scientific, Waltham, MA), DEFA5 (HUF101588, AssayGenie, Dublin, Ireland), FABP2
144 (EHFABP2, ThermoFisher Scientific, Waltham, MA), and REG3A (EH390RB, ThermoFisher
145 Scientific, Waltham, MA). Urine samples were prepared, desalted, and quantified as described
146 above. For each sample, triplicate measurements of 0.2, 2, 10, or 20 μg total protein were
147 plated based on anticipated protein abundance to fit within the range of the standard curve for
148 each ELISA.

149

150 *Ingenuity Pathway Analysis*

151 Network analysis and pathway enrichment were predicted using Ingenuity Pathway
152 Analysis (IPA) (QIAGEN digital insights, Redwood City, CA, USA, accessed on June 20, 2023).

153 IPA was used to generate a core analysis using all 99 differentially abundant proteins (**Table 2**)
154 based on differential median fold change expression ($\text{Log}_2 \pm 1.1$) and Mann-Whitney U-test
155 significance ($P < 0.05$) cut-offs.

156

157 *Statistical analysis*

158 Proteins above a Log_2 median fold change RFU of 1.1 and a statistical significance of P
159 < 0.05 for the comparison between samples from infants with NEC and controls were selected
160 for detailed analysis. Samples were analyzed for the influence of multiple comparisons using a
161 false discovery rate (FDR) of < 0.05 . Volcano plots, hierarchical cluster analysis, and
162 Spearman's r correlation matrices were performed using Log_2 RFU median fold change values.
163 Log_{10} RFU values were used for comparative statistical analysis for violin plots and receiver
164 operator characteristics (ROC). Statistical significance was determined by a Mann-Whitney U-
165 test, non-parametric Wilcoxon test, or Kruskal Wallis as indicated. Combined ROC curves were
166 generated using multiple logistic regression. Comparative statistical analysis was performed
167 using GraphPad 9.3.1 (San Diego, USA). Hierarchical clustering was generated in R-studio
168 version 4.2.0 using the "heatmap.2" package by Ward clustering.

169

170 **Results**

171 *Cohort characteristics*

172 The cohort included infants ($n = 28$) born between 24 and 36 weeks gestation and
173 divided into age- and self-matched cohorts (**Table 1**). For the age-matched cohort, infants were

174 enrolled at the time of NEC diagnosis ($n = 8$) and matched with infants who did not develop
175 NEC (controls, $n = 8$). For the self-matched cohort, infants were initially enrolled as controls but
176 then developed NEC ($n = 12$). Samples obtained before NEC diagnosis were used as the
177 control for this group, with six days being the shortest interval between a control sample and a
178 diagnosis of NEC.

179

180 ***Qualitative and quantitative proteomic analysis of urine proteins***

181 A total of 7596 proteins were screened in the urine samples using an aptamer-based
182 proteomics microarray (SomaScan[®]). For the age-matched cohort, 150 urine proteins were
183 significantly different between the infants with NEC and controls, based on Log₂ median fold
184 change RFU of ± 1.1 and Mann-Whitney U-test of $P < 0.05$ (**Figure 1A**). For the self-matched
185 cohort, 360 urine proteins were differentially abundant in the control compared to the NEC
186 samples (**Figure 1B**). There were 99 proteins shared between the age- and self-matched
187 groups, and these will be the focus of the remainder of the analysis (**Figure 1C**). Of these 99
188 proteins, 35 were increased, and 64 were decreased between infants with NEC and their
189 respective controls. A summary of the identified proteins in the combined cohort is provided in
190 **Table S1**. Due to the small sample size of the cohort, only 10 proteins of the 7596 in the
191 microarray survived multiple testing correction by false discovery rate (FDR < 0.05). Of the
192 proteins that survived this correction, interleukin 36B (IL36B, FDR = 0.024) and interleukin 36
193 receptor antagonist (IL36RN, FDR = 0.024) were in the subset of proteins that were significantly
194 different between the infants with NEC and controls.

195 We next identified two protein panels of interest for further analysis. Protein panel one
196 consisted of four proteins chosen for their primary localization within the intestine and previously
197 observed association with NEC and/or inflammation (**Table 2**). These include regenerating
198 family member 1 beta (REG1B), regenerating islet-derived protein 3 alpha (REG3A), intestinal
199 fatty acid binding protein 2 (FABP2), and defensin 5 alpha (DEFA5). Protein panel 2 consisted
200 of proteins chosen based on the magnitude of the fold change between patients with NEC and
201 controls, as well as the best area under the curve (AUC) values (**Table 2**). Panel 2 included
202 REG1B (also in panel 1), single-stranded DNA binding protein 1 (SSBP1), crystallin zeta-like 1
203 (CRYZL1), integral membrane protein 2B (ITM2B), IL36B, and IL36RN.

204 We analyzed the association between the relative protein levels for the most differentially
205 abundant proteins using an inter-protein Spearman's r correlation matrix (**Figure 2A**). With a
206 focus on our protein panels, we found that for panel 1, DEFA5 and REG3A had the strongest
207 correlation ($r = 0.83$) (**Figure 2B**). In addition, REG3A ($r = 0.57$) and DEFA5 ($r = 0.46$) had
208 strong positive correlations to REG1B (**Figure 2B**). For protein panel 2, there was a strong
209 negative correlation with IL36RN with REG1B ($r = -0.63$) (**Figure 2C**). In addition, SSBP1
210 correlated positively with ITM2B ($r = 0.62$) and negatively with CRYZL1 ($r = -0.52$) and IL36B (r
211 $= -0.45$) (**Figure 2C**).

212 We next used hierarchical cluster analysis to visualize patterns in protein abundance
213 across patient pairs and disease severity (**Figure 3**). We found that the pattern of relative fold
214 change of the proteins was consistent across samples. In addition, age-matched and self-
215 matched samples did not cluster together, but samples did cluster based on disease severity,
216 with noted clustering of samples from patients with Bell's stage III NEC (**Figure 3**).

217

218 ***Analysis of protein abundance and comparison based on disease severity.***

219 Violin plots were used to visualize the protein abundance in urine samples for the
220 proteins in panel 1, with significant differences noted between controls and patients with NEC
221 (**Figure 4A**). We further analyzed the differences in urine protein abundance based on disease
222 severity as defined by modified Bell's stage (**Figure 4B**). REG1B was significantly increased in
223 infants with NEC Bell's stage II compared to controls ($P < 0.01$) as well as in Bell's stage III vs.
224 controls ($P < 0.01$). REG3A and DEFA5 were significantly increased in the urine of infants with
225 NEC Bell's stage III vs. controls (REG3A: $P < 0.0001$, DEFA5: $P < 0.0005$) and in Bell's stage II
226 compared to Bell's stage III (REG3A: $P < 0.01$, DEFA5: $P < 0.01$). FABP2 was only significantly
227 increased Bell's stage III vs. controls ($P < 0.05$).

228 ELISAs were used to validate the relative protein abundance detected with the protein
229 microarray. We selected the proteins in panel 1, REG1B, REG3A, FABP2, and DEFA5
230 (**Supplementary Figure S1**) for validation. REG1B (**Figure S1A**) and DEFA5 (**Figure S1C**)
231 were both significantly increased in NEC relative to controls; however, REG3A (**Figure S1B**)
232 and FABP2 (**Figure S1D**) were not significantly different in NEC compared to controls
233 (**Supplementary Table S2**). This likely occurred because levels of the urine proteins were
234 below the limit of detection for the ELISAs for some patients, which resulted in an inability to
235 detect differences between patients with NEC and controls. These assays were limited by the
236 volume of urine obtainable from preterm neonates and the low concentration of the proteins of
237 interest. Thus, the microarray data was used for the remainder of the analysis due to increased
238 sensitivity at lower protein concentrations.

239 Analysis of the ability of these proteins to serve as potential biomarkers was performed
240 by calculating the AUC (**Table 2** and **Figure 4C**). Values above 0.7 are considered acceptable,
241 and above 0.8 are considered excellent for a diagnostic test. REG1B (0.82, 95% CI 0.69-0.95)
242 and REG3A (0.79, 95% CI 0.69-0.95) were the most effective at differentiating between patients
243 with NEC and controls (**Figure 4C**).

244 We performed a similar analysis for the proteins in panel 2. The RFU data for the urine
245 samples from patients with NEC and controls is shown in **Figure 5A**. We also analyzed the
246 ability of these proteins to differentiate between patients based on NEC severity (**Figure 5B**).
247 We found that CRYZL1, ITM2B, IL36B, and IL36RN were significantly different between infants
248 with Bell's stage II NEC relative to controls ($P < 0.05$). SSBP1 ($P < 0.005$) and IL36B ($P < 0.05$)
249 were significantly different between infants with NEC Bell's Stage II and III.

250 ROC curves were generated for all proteins in panel 2. All of the proteins in panel 2 were
251 effective at differentiating between infants with NEC and controls (**Figure 5C**). IL36B (0.86, 95%
252 CI 0.74-0.98) and IL36RN (0.91, 95% CI 0.82-0.99) had the best AUC values and have the
253 potential to serve as excellent diagnostic tests.

254

255 *Diagnostic utility of protein panels*

256 We generated combined ROC curves for groups of proteins to determine if this would
257 improve their diagnostic utility as urine biomarkers (**Figure 6**). We found that protein panel 1
258 (**Figure 6A**, AUC 0.9, 95% CI 0.8-1), protein panel 2 (**Figure 6B**, AUC 0.98, 95% CI 0.95-1),
259 and the combination of IL-36B and IL36RN (**Figure 6C**, AUC 0.94, 95% CI 0.86-1) had an
260 outstanding ability to differentiate between infants with NEC and controls.

261 *Upstream regulators and statistical enrichment*

262 Ingenuity pathway analysis (IPA) was used to predict activated or inhibited upstream
263 regulators and signaling pathways. IPA predicts differentially activated regulators measured by
264 downstream enrichment scores (overlap P -value) and activation states (activation z -score) [23].
265 Upstream regulator analysis (URA) predicts direct relationships between upstream regulators
266 and downstream molecules using the protein dataset. Causal analysis (CNA) tools further
267 predict upstream master regulators that may have multiple indirect relationships, nodes, and
268 links. Upstream regulators of interest (linked to inflammation) by URA and CNA were predicted
269 and summarized in **Table 3**.

270 URA predicted several direct regulators based on the downstream status of the
271 differentially abundant proteins identified in the urine samples. This includes regulators of lipid
272 metabolism, sterol regulatory element binding protein 1 (SREBF1, $z = 1.95$, $P = 0.00015$), and
273 retinoic acid receptor alpha (RXRA, $z = 1.94$, $P = 0.00794$) (**Table 3**). In addition, the
274 polyfunctional cytokine IL-22 ($z = 1.96$, $P = 0.00091$) was predicted as activated based on the
275 differential abundance of REG1B (+), REG3A (+), LBP (+), and TGM3 (-) (**Supplementary**
276 **Figure S2, Table 3**).

277 CNA includes indirect relationships and linked nodes to identify upstream-master
278 regulators (**Table 3**). Predicted master regulators included: TNF receptor-associated factor 1B
279 (TRAF2) ($z = 2.353$, network bias corrected $P = 0.0003$), which plays a role in NF κ B and JNK
280 signaling pathways [24], mRNA decay activator protein ZFP36 ($z = 2.263$, network bias
281 corrected $P = 0.0153$), which is involved in cytokine degradation and regulates the TNF-alpha
282 feedback loop through mRNA destabilization [25,26], Endoribonuclease ZC3H12A ($z = 2.191$,

283 network bias corrected $P = 0.043$), and IL-22 ($z = 2.0$, network bias corrected $P = 0.0171$).
284 STAT3, which is activated by IL-22 and other cytokines, was upstream of several differentially
285 abundant proteins in this study (**Supplementary Figure S2, Table 3**).

286

287 **Discussion**

288 In this study, we used an aptamer-based protein microarray to successfully identify a
289 subset of urine proteins that differentiated between infants with and without NEC. The validity of
290 our data was supported by the fact that patterns of relative protein abundance in the urine were
291 consistent across both age- and self-matched cohorts. In addition, the protein levels in the urine
292 of these patient cohorts clustered based on the severity of NEC. Our identified biomarker panels
293 had excellent diagnostic potential based on AUC values, supporting further studies investigating
294 these proteins of interest as potential biomarkers.

295 Our study focused on urine as the biological source for biomarker testing, given that it is
296 an easily obtainable specimen even for tiny preterm neonates. Unfortunately, the detection of
297 biomarkers in urine adds additional analytical challenges due to sample-to-sample biological
298 variability. This includes significant variability in hydration states, glomerular filtration rates
299 (GFR), and differential abundance in carrier proteins and metabolites [27]. The accurate
300 quantitation of differentially abundant proteins measured in urine is likely improved using a
301 reference marker. Typical urine reference markers require a constitutively expressed gene or
302 metabolite unaffected by the disease. Studies have tried to identify a reliable normalization
303 reference using urinary proteins or peptides to adjust for urinary dilution [7]. These have
304 included serum albumin, collagen, and urine creatinine; however, protein and metabolite

305 variability based on the developmental age of neonates complicates normalization [28]. For
306 example, urine albumin and creatinine concentrations in neonates have been shown to be
307 inconsistent in preterm infants [29]. The consistency of our protein abundance patterns with two
308 different patient matching strategies and across a range of corrected gestational ages indicates
309 that these technical issues were likely minimized by using equivalent protein loading, as was
310 performed in our studies.

311 Based on published data, the likely intestinal origin of many of the proteins we detected
312 provides another degree of complexity, as it requires proteins or peptides to enter the
313 bloodstream from the intestine and be filtered by the glomeruli in the kidney to be identified in
314 the urine. In addition, biomarkers need to distinguish NEC from non-specific inflammation in the
315 kidneys and urinary tract to have clinical significance. In this study, known biomarkers for urinary
316 tract infections [30] and acute kidney injury [31], specifically NGAL (Lipocalin-2) and CST3
317 (Cystatin C), were not significantly abundant. In addition, the consistency of protein abundance
318 patterns across matching strategies and the clustering of patients based on disease severity
319 supports a NEC-specific protein signature independent of renal complications.

320 In this study, we developed two protein panels and identified a pair of proteins with
321 excellent AUC values for diagnostic studies. Using a protein panel increases the power of a
322 diagnostic test to accurately discriminate between healthy and diseased states. Although a
323 single disease biomarker would be optimal, this is likely unfeasible given the complexity of the
324 pathogenesis of NEC. Below, we discuss the specific proteins we incorporated into our panels.

325 *REG1B and REG3A*

326 Regenerating islet-derived proteins (REGs) have multifunctional roles in cellular
327 processes, including promoting differentiation, increasing cellular proliferation, preventing
328 apoptosis, and enhancing host defense [32]. REG proteins (18-19 kDa) have been discovered
329 in multiple tissues and diseases, and they are typically expressed at sites of inflammation [33].
330 REG1B and REG3A recognize bacterial peptidoglycan and reduce bacterial membrane integrity
331 [34]. They are increased in inflammatory bowel disease (IBD), specifically ulcerative colitis (UC)
332 [35]. REG1B expression is also increased in the intestine during NEC [36]. In addition,
333 increased REG1B expression drives intestinal crypt regeneration [37]. REG3A has anti-
334 apoptotic effects and increases enterocyte viability by reducing caspase cleavage [38]. REG1B
335 [39] and REG3A [40] have been identified as potential stool biomarkers for enteropathy and
336 environmental enteric dysfunction (EED). Finally, REG1B and REG3A are induced by the IL-22
337 signaling pathway [41], which is protective in the intestine of mice during experimental NEC [42].

338 *FABP2*

339 Fatty acid binding protein 2 (FABP2) is a 15 kDa enterocyte-specific carrier protein
340 involved in intracellular fatty acid translocation across the gut barrier [43]. FABPs are subdivided
341 into intestinal (FABP2), hepatic (FABP1), and adipose (FABP4) variants based on localization.
342 FABP2, FABP1, and FABP4 were all differentially abundant in our proteomic assay
343 (**Supplementary Table 1**). FABP2 has previously been identified as differentially abundant
344 during intestinal barrier dysfunction [44] and, specifically, NEC in several biomarker studies of
345 stool and urine [45]. A clinical metadata study showed a high FABP2 level was an indicator of
346 NEC, but many studies were limited in sample size and had difficulty consistently normalizing
347 urine samples by creatinine [12].

348 *DEFA5*

349 Human α -defensin (DEFA5) (10 kDa) is a powerful antimicrobial host defense protein
350 [46]. It is primarily expressed by intestinal Paneth cells and stored intracellularly as a zymogen.
351 After secretion, DEFA5 is activated by trypsin and regulated by Paneth cell-derived serine
352 protease inhibitors, which play a role in selectively maintaining gut microbiome diversity. One
353 study has linked increased expression with urinary tract infections [47]. Increased DEFA5 has
354 previously been detected in the stool of infants with NEC via proteomics [48] and in intestinal
355 samples resected from infants with NEC via RNA sequencing [49]. In addition, altered stool
356 *DEFA5* methylation patterns have been observed during NEC [50].

357 *SSBP1*

358 Single-stranded DNA binding protein 1 (SSBP1) is a ubiquitously expressed protein
359 involved in mitochondrial biogenesis. Mitochondrial damage, through the presence of
360 mitochondrial DNA and proteins in urine, has been used as a marker for tissue damage during
361 inflammation [51]. In addition, SSBP1, through heat shock factor 1 (HSF1) signaling, has been
362 linked to increased expression of heat shock protein 70 (Hsp70) [52]. Hsp70 protects cells from
363 proteolytic stress and regulates pro-inflammatory Toll-like receptor (TLR)-induced cytokines [53].
364 In enterocytes, activation of TLR4 leads to upregulation of Hsp70, and Hsp70 signaling has
365 been identified as a potential counter-regulatory mechanism that opposes TLR4 signaling during
366 NEC [54].

367 *CRYZL1*

368 Crystallin zeta-like 1 (CRYZL1) is ubiquitously expressed and shares sequence
369 homology with zeta crystallin or quinone oxidoreductase 1 (NQO1). While the role of CRYZL1 is

370 unclear, NQO1 protects against cellular damage by acting as a redox switch interacting with
371 multiple proteins, mRNA, and NADH [55]. Upregulation of *Nqo1* expression has been
372 associated with protection from NEC-like injury in rats [56].

373 *ITM2B*

374 Integral membrane protein 2B (ITM2B) is found in all tissue types. Its exact function
375 needs to be delineated, although it is thought to play a role in apoptosis, mitochondrial
376 homeostasis, and processing of amyloid precursor proteins [57].

377 *IL36B and IL36RN*

378 Interleukin 36 (IL-36) proteins are a family of inflammatory cytokines and consist of
379 agonists IL36 (α , β , γ) and a receptor antagonist, IL36RN (IL36Ra). IL-36 dysregulation is
380 associated with inflammatory diseases, including psoriasis, arthritis, and IBD [58]. In addition,
381 IL-36 regulates both immune and non-immune cells in a feedback loop where IL-22, IL-17A, and
382 TNF α induce all three IL-36 family cytokines, and IFN γ is selective for inducing IL36B [59].
383 Interestingly, in mice with NEC, increased IL36B was detected only in the ileum, and an
384 increased IL36B: IL36RN ratio was associated with NEC [60]. In our study, the relative decrease
385 in IL36RN is consistent with increased inflammation, whereas the reduction in IL36B is not
386 expected and needs further exploration in mechanistic studies.

387 *Upstream regulator network analysis*

388 IPA identified several potential upstream and mechanistic regulators. Notably, IL-22 was
389 predicted to be an upstream regulator based on the downstream differential abundance of
390 REG1B, REG3A, LPS-binding protein (LBP), and transglutaminase 3 (TGM3). IL-22, through

391 STAT3-dependent signaling [61], is involved in intestinal barrier protection and induces
392 proliferation in intestinal stem cells and goblet cell proliferation in the crypts [62]. Of note, STAT3
393 is activated by cytokines other than IL-22, such as IL-6 and IL-10 family cytokines [63]. The
394 redundancy in these pathways makes it difficult to pinpoint the upstream mediators without
395 mechanistic data; however, the increased abundance of these intestinal proteins in the urine of
396 infants with NEC indicates a potential increase in signaling via STAT3 activating cytokines
397 and/or is reflective of a weakened gut barrier in patients with NEC. Additionally, hepcidin
398 (HAMP), which had a 3-fold increased abundance in the samples from infants with NEC, is an
399 antimicrobial iron sequestering protein and is also positively regulated by IL-22 [64]. Moreover,
400 IL-22 is a complex and polyfunctional cytokine. We have previously shown that administration of
401 recombinant IL-22 is protective against intestinal injury during experimental NEC in mice [42];
402 however, further studies are needed to determine the balance between protective and
403 inflammatory roles for this cytokine in NEC.

404

405 **Conclusion**

406 Due to the rapid and unpredictable onset of NEC, a biomarker needs to be readily
407 available, non-invasive, rapidly tested, and able to identify NEC prior to the advanced Bell's
408 stages. In this study, we identify proteins of interest that have the potential to serve as
409 biomarkers that are so urgently needed to improve the care of infants with NEC. While our
410 results need to be validated in a large cohort of infants with diverse physiologic and
411 inflammatory conditions, this study will serve as an important foundation for future studies on a
412 larger, diverse cohort.

413

414 **List of abbreviations**

415 Necrotizing enterocolitis (NEC), receiver operator characteristics (ROC), area under the curve
416 (AUC), relative fluorescence units (RFU), false discovery rate (FDR), Ingenuity pathway
417 analysis (IPA), Upstream regulator analysis (URA), and Causal analysis (CNA).

418

419 **Declarations**

420 **Ethics approval and consent to participate**

421 After consent was obtained, samples were prospectively collected from infants admitted to the
422 St. Louis Children's Hospital Neonatal Intensive Care Unit (NICU) in St. Louis, Missouri, USA.
423 Enrollment was conducted according to protocols approved by the Washington University in St.
424 Louis School of Medicine Institutional Review Board (IRB protocol numbers 201706182 and
425 201802101).

426

427 **Funding**

428 LCF is supported by a Thrasher Research Fund Early Career Award, UNC School of Medicine
429 Physician Scientist Training Program Faculty Award, and UNC Children's Development Early
430 Career Investigator Grant through the generous support of donors to UNC. MG is supported by
431 National Institutes of Health (NIH) grants R01DK124614, R01DK118568, R01HD105301,
432 R44HD110306, the Chan Zuckerberg Initiative Grant number 2022-316749, and the University
433 of North Carolina at Chapel Hill Department of Pediatrics.

434

435 **Availability of data and materials**

436 All data generated or analyzed during this study are included in this published article and its
437 supplementary information files.

438

439 **Disclosure statement**

440 The authors report that there are no competing interests to declare.

441

442 **Authors contributions**

443 Manuscript preparation by SM, LF, CM, and MG. Critical review of the manuscript by all authors.
444 Data analysis by SM and LF. Research coordination and sample processing by QG, OD, GB,
445 and MG. Study design by SM, LF, and MG.

446

447 **Acknowledgements**

448 We want to thank the neonates and families who participated in our study. We would also like to
449 thank the staff at St. Louis Children's Hospital Neonatal Intensive Care Unit in St. Louis,
450 Missouri, USA, for all their hard work in helping to collect samples, which made this study
451 possible.

452

453

454 **Figure Legends**

455 **Graphical abstract.** Overview of study findings. Created with Biorender.com

456

457 **Figure 1. Volcano plots depicting the relative abundance of urine proteins in infants with**
458 **and without NEC.** Urine protein levels were compared between infants with and without NEC in
459 the **(A)** Age-matched cohort ($n = 8$ pairs), **(B)** Self-matched cohort ($n = 12$ pairs), or **(C)** both
460 groups combined ($n = 20$ pairs). Differentially abundant proteins are presented on a volcano plot
461 with a median fold change of RFU values ($\text{Log}_2 \pm 1.1$) and P -value ($-\text{Log}_{10}$ Mann Whitney U-test,
462 $P = 0.05$) depicted as red lines. Proteins of interest are labeled red (Protein panel 1) or blue
463 (Protein panel 2). REG1B was included in both panels.

464

465 **Figure 2. Correlation between relative protein levels in the urine of infants with and**
466 **without NEC.** **(A)** Spearman's r correlation was used to determine the correlation of relative
467 protein abundance for the entire cohort ($n = 20$ pairs). The directionality of the median fold
468 change for NEC vs. non-NEC is depicted by red (increased) and blue (decreased) arrows.
469 Protein panel 1 (●). Protein panel 2 (○). REG1B was included in both panels. Correlation
470 matrices were generated for protein panels 1 **(B)** and 2 **(C)**.

471

472 **Figure 3. Relative protein levels in matched urine samples for pairs of infants with and**
473 **without NEC cluster based on Bell's Stage, a marker of NEC severity.** Hierarchical cluster
474 analysis demonstrating median fold change in protein abundance for sample pairs. The

475 directionality of the median fold change for NEC vs. control is depicted by red (increased) and
476 blue (decreased) arrows. Protein panel 1 (●). Protein panel 2 (○). The black box delineates
477 patients with Bell's Stage III NEC.

478

479 **Figure 4. Urine proteins in protein panel 1 differ between infants with NEC and controls,**
480 **as well as based on Bell's stage.** The proteins in panel 1 include REG1B, REG3A, DEFA5,
481 and FABP2. (A) Comparison of protein abundance for infants with NEC and controls. Line
482 indicates median. Dots indicate individual infants. * $P < 0.05$, ** $P < 0.01$ by non-parametric
483 Wilcoxon test. (B) Samples were stratified based on disease severity using modified Bell's
484 stage. Line indicates median. Dots indicate individual infants. ns, $P > 0.05$, * $P < 0.05$, **
485 $P < 0.01$, *** $P < 0.0005$, **** $P < 0.0001$ by Kruskal Wallis. (C) ROC curves with AUC values
486 and 95% CI.

487

488 **Figure 5. Urine proteins in protein panel 2 differ between infants with NEC and controls,**
489 **as well as based on Bell's stage.** (A) Comparison of protein abundance for infants with NEC
490 and controls. Line indicates median. Dots indicate individual infants. * $P < 0.05$, ** $P < 0.01$, ***
491 $P < 0.005$, **** $P < 0.0001$ by non-parametric Wilcoxon test. (B) Samples were stratified based
492 on disease severity using modified Bell's stage. Line indicates median. Dots indicate individual
493 infants. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.005$ by Kruskal Wallis. (C) ROC curves with AUC values
494 and 95% CI.

495

496 **Figure 6. Combinations of select urine proteins very effectively discriminate between**
497 **infants with and without NEC.** Combined ROC curves were generated for (A) Protein panel 1
498 (REG1B, REG3A, DEFA5, and FABP2), (B) Protein panel 2 (REG1B, SSBP1, CRYZL1, ITM2B,
499 IL36B, and IL36RN) and (C) IL-36 and IL36RN. AUC values with the 95% CI are shown.

500

501 **Supplementary Figure S1. ELISA validation of urine protein levels for controls and**
502 **infants with NEC.** (A) REG1B, (B) REG3A, (C) DEFA5, and (D) FABP2 were measured in the
503 urine of all infants in the study via ELISA. Samples with protein levels below the limit of
504 detection were censored. Bar indicates median. n = number of patients with detectable urine
505 protein. ns, $P > 0.05$, * $P < 0.05$, ** $P < 0.01$ via Mann Whitney U-test.

506

507 **Supplementary Figure S2. IL-22 and STAT3 are upstream regulators of proteins that are**
508 **differentially abundant in the urine of infants with and without NEC.** (A) Upstream regulator
509 analysis (URA) predicted IL-22 as a direct regulator based on the downstream state of REG1B
510 (+), REG3A (+), LBP (+), and TGM3 (-). (B) Causal network analysis (CNA) mapped indirect
511 relationships, which included IL-22 and STAT3. Proteins marked in red and green were
512 increased and decreased, respectively. Orange and blue proteins and interactions indicate
513 predicted activation and inhibition, respectively. Yellow and grey lines indicate interactions that
514 are inconsistent or not predicted with the state of the downstream molecule. Dashed and solid
515 lines indicate indirect and direct relationships, respectively.

516

517 References

- 518 [1] Battersby C, Santhalingam T, Costeloe K, et al. Incidence of neonatal necrotising
519 enterocolitis in high-income countries: a systematic review. *Arch Dis Child Fetal*
520 *Neonatal Ed.* 2018 Mar;103(2):F182-f189.
- 521 [2] Goldstein GP, Sylvester KG. Biomarker Discovery and Utility in Necrotizing Enterocolitis.
522 *Clinics in Perinatology.* 2019 2019/03/01;46(1):1-17.
- 523 [3] Nagpal R, Tsuji H, Takahashi T, et al. Gut dysbiosis following C-section instigates higher
524 colonisation of toxigenic *Clostridium perfringens* in infants. *Benef Microbes.* 2017 May
525 30;8(3):353-365.
- 526 [4] Adams JM, Valentine CJ, Karns RA, et al. DHA Supplementation Attenuates
527 Inflammation-Associated Gene Expression in the Mammary Gland of Lactating Mothers
528 Who Deliver Preterm. *J Nutr.* 2022 Jun 9;152(6):1404-1414.
- 529 [5] Sampah MES, Hackam DJ. Dysregulated Mucosal Immunity and Associated
530 Pathogeneses in Preterm Neonates. *Front Immunol.* 2020;11:899.
- 531 [6] Singh DK, Miller CM, Orgel KA, et al. Necrotizing enterocolitis: Bench to bedside
532 approaches and advancing our understanding of disease pathogenesis [Review].
533 *Frontiers in Pediatrics.* 2023 2023-January-11;10.
- 534 [7] Wang K, Tao G, Sun Z, et al. Recent Potential Noninvasive Biomarkers in Necrotizing
535 Enterocolitis. *Gastroenterol Res Pract.* 2019;2019:8413698.
- 536 [8] Wang K, Tao G, Sun Z, et al. Recent Potential Noninvasive Biomarkers in Necrotizing
537 Enterocolitis. *Gastroenterology Research and Practice.* 2019 2019/04/22;2019:8413698.
- 538 [9] Agakidou E, Agakidis C, Gika H, et al. Emerging Biomarkers for Prediction and Early
539 Diagnosis of Necrotizing Enterocolitis in the Era of Metabolomics and Proteomics. *Front*
540 *Pediatr.* 2020;8:602255.
- 541 [10] Donda K, Torres BA, Maheshwari A. Non-coding RNAs in Neonatal Necrotizing
542 Enterocolitis. *Newborn (Clarksville).* 2022 Jan-Mar;1(1):120-130.
- 543 [11] Galley JD, Mar P, Wang Y, et al. Urine-derived extracellular vesicle miRNAs as possible
544 biomarkers for and mediators of necrotizing enterocolitis: A proof of concept study.
545 *Journal of Pediatric Surgery.* 2021 2021/11/01;56(11):1966-1975.
- 546 [12] Liu Y, Jiang L-F, Zhang R-P, et al. Clinical significance of FABP2 expression in newborns
547 with necrotizing enterocolitis. *World Journal of Pediatrics.* 2016 2016/05/01;12(2):159-
548 165.
- 549 [13] Chaaban H, Markel TA, Canvasser J, et al. Biobanking for necrotizing enterocolitis:
550 Needs and standards. *J Pediatr Surg.* 2020 Jul;55(7):1276-1279.
- 551 [14] Ralls MW, Gadepalli SK, Sylvester KG, et al. Development of the necrotizing
552 enterocolitis society registry and biorepository. *Semin Pediatr Surg.* 2018 Feb;27(1):25-
553 28.
- 554 [15] Soomro S, Venkateswaran S, Vanarsa K, et al. Predicting disease course in ulcerative
555 colitis using stool proteins identified through an aptamer-based screen. *Nat Commun.*
556 2021 Jun 28;12(1):3989.
- 557 [16] Vanarsa K, Castillo J, Wang L, et al. Comprehensive proteomics and platform validation
558 of urinary biomarkers for bladder cancer diagnosis and staging. *BMC Medicine.* 2023
559 2023/04/05;21(1):133.

- 560 [17] Dong L, Watson J, Cao S, et al. Aptamer based proteomic pilot study reveals a urine
561 signature indicative of pediatric urinary tract infections. *PLoS One*.
562 2020;15(7):e0235328.
- 563 [18] Billing AM, Ben Hamidane H, Bhagwat AM, et al. Complementarity of SOMAScan to LC-
564 MS/MS and RNA-seq for quantitative profiling of human embryonic and mesenchymal
565 stem cells. *J Proteomics*. 2017 Jan 6;150:86-97.
- 566 [19] Neu J, Modi N, Caplan M. Necrotizing enterocolitis comes in different forms: Historical
567 perspectives and defining the disease. *Semin Fetal Neonatal Med*. 2018 Dec;23(6):370-
568 373.
- 569 [20] Bell MJ, Ternberg JL, Feigin RD, et al. Neonatal necrotizing enterocolitis. Therapeutic
570 decisions based upon clinical staging. *Ann Surg*. 1978 Jan;187(1):1-7.
- 571 [21] Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria.
572 *Pediatr Clin North Am*. 1986 Feb;33(1):179-201.
- 573 [22] Gold L, Ayers D, Bertino J, et al. Aptamer-based multiplexed proteomic technology for
574 biomarker discovery. *PLoS One*. 2010 Dec 7;5(12):e15004.
- 575 [23] Krämer A, Green J, Pollard J, Jr., et al. Causal analysis approaches in Ingenuity
576 Pathway Analysis. *Bioinformatics*. 2014 Feb 15;30(4):523-30.
- 577 [24] Lee SY, Reichlin A, Santana A, et al. TRAF2 is essential for JNK but not NF-kappaB
578 activation and regulates lymphocyte proliferation and survival. *Immunity*. 1997
579 Nov;7(5):703-13.
- 580 [25] Kuiken HJ, Egan DA, Laman H, et al. Identification of F-box only protein 7 as a negative
581 regulator of NF-kappaB signalling. *J Cell Mol Med*. 2012 Sep;16(9):2140-9.
- 582 [26] Carballo E, Lai WS, Blakeshear PJ. Feedback inhibition of macrophage tumor necrosis
583 factor-alpha production by tristetraprolin. *Science*. 1998 Aug 14;281(5379):1001-5.
- 584 [27] Jantos-Siwy J, Schiffer E, Brand K, et al. Quantitative urinary proteome analysis for
585 biomarker evaluation in chronic kidney disease. *J Proteome Res*. 2009 Jan;8(1):268-81.
- 586 [28] Sylvester KG, Moss RL. Urine biomarkers for necrotizing enterocolitis. *Pediatr Surg Int*.
587 2015 May;31(5):421-9.
- 588 [29] Sanderson K, O'Shea TM, Kistler CE. An Individualized Approach to Kidney Disease
589 Screening in Children With a History of Preterm Birth. *Clin Pediatr (Phila)*. 2023
590 Jun;62(5):385-388.
- 591 [30] Horváth J, Wullt B, Naber KG, et al. Biomarkers in urinary tract infections - which ones
592 are suitable for diagnostics and follow-up? *GMS Infect Dis*. 2020;8:Doc24.
- 593 [31] Vaidya R, Yi J, O'Shea T, et al. Long-Term Outcome of Necrotizing Enterocolitis and
594 Spontaneous Intestinal Perforation. *Pediatrics*. 2022 10/06;150.
- 595 [32] Cash HL, Whitham CV, Behrendt CL, et al. Symbiotic bacteria direct expression of an
596 intestinal bactericidal lectin. *Science*. 2006 Aug 25;313(5790):1126-30.
- 597 [33] Sun C, Wang X, Hui Y, et al. The Potential Role of REG Family Proteins in Inflammatory
598 and Inflammation-Associated Diseases of the Gastrointestinal Tract. *Int J Mol Sci*. 2021
599 Jul 3;22(13).
- 600 [34] Mukherjee S, Hooper Lora V. Antimicrobial Defense of the Intestine. *Immunity*. 2015
601 2015/01/20;42(1):28-39.
- 602 [35] van Beelen Granlund A, Østvik AE, Brenna Ø, et al. REG gene expression in inflamed
603 and healthy colon mucosa explored by in situ hybridisation. *Cell Tissue Res*. 2013
604 Jun;352(3):639-46.

- 605 [36] Egozi A, Olaloye O, Werner L, et al. Single-cell atlas of the human neonatal small
606 intestine affected by necrotizing enterocolitis. *PLOS Biology*. 2023;21(5):e3002124.
- 607 [37] Peterson KM, Guo X, Elkahloun AG, et al. The expression of REG 1A and REG 1B is
608 increased during acute amebic colitis. *Parasitol Int*. 2011 Sep;60(3):296-300.
- 609 [38] Zhang MY, Wang J, Guo J. Role of Regenerating Islet-Derived Protein 3A in
610 Gastrointestinal Cancer. *Front Oncol*. 2019;9:1449.
- 611 [39] Peterson KM, Buss J, Easley R, et al. REG1B as a predictor of childhood stunting in
612 Bangladesh and Peru. *Am J Clin Nutr*. 2013 May;97(5):1129-33.
- 613 [40] Bein A, Fadel CW, Swenor B, et al. Nutritional deficiency in an intestine-on-a-chip
614 recapitulates injury hallmarks associated with environmental enteric dysfunction. *Nat*
615 *Biomed Eng*. 2022 Nov;6(11):1236-1247.
- 616 [41] Rae J, Hackney J, Huang K, et al. Identification of an IL-22-Dependent Gene Signature
617 as a Pharmacodynamic Biomarker. *International Journal of Molecular Sciences*.
618 2021;22(15):8205.
- 619 [42] Mihi B, Gong Q, Nolan LS, et al. Interleukin-22 signaling attenuates necrotizing
620 enterocolitis by promoting epithelial cell regeneration. *Cell Rep Med*. 2021 Jun
621 15;2(6):100320.
- 622 [43] Huang X, Zhou Y, Sun Y, et al. Intestinal fatty acid binding protein: A rising therapeutic
623 target in lipid metabolism. *Prog Lipid Res*. 2022 Jul;87:101178.
- 624 [44] Lau E, Marques C, Pestana D, et al. The role of I-FABP as a biomarker of intestinal
625 barrier dysfunction driven by gut microbiota changes in obesity. *Nutrition & Metabolism*.
626 2016;13.
- 627 [45] Reisinger KW, Derikx JPM, Thuijls G, et al. Noninvasive measurement of intestinal
628 epithelial damage at time of refeeding can predict clinical outcome after necrotizing
629 enterocolitis. *Pediatric Research*. 2013 2013/02/01;73(2):209-213.
- 630 [46] Ganz T. Defensins: antimicrobial peptides of innate immunity. *Nat Rev Immunol*. 2003
631 Sep;3(9):710-20.
- 632 [47] Spencer JD, Hains DS, Porter E, et al. Human alpha defensin 5 expression in the human
633 kidney and urinary tract. *PLoS One*. 2012;7(2):e31712.
- 634 [48] Gagne D, Shajari E, Thibault MP, et al. Proteomics Profiling of Stool Samples from
635 Preterm Neonates with SWATH/DIA Mass Spectrometry for Predicting Necrotizing
636 Enterocolitis. *Int J Mol Sci*. 2022 Oct 1;23(19).
- 637 [49] Tremblay É, Thibault M-P, Ferretti E, et al. Gene expression profiling in necrotizing
638 enterocolitis reveals pathways common to those reported in Crohn's disease. *BMC*
639 *Medical Genomics*. 2016 2016/01/22;9(1):6.
- 640 [50] Klerk DH, Plösch T, Verkaik-Schakel RN, et al. DNA Methylation of TLR4, VEGFA, and
641 DEFA5 Is Associated With Necrotizing Enterocolitis in Preterm Infants. *Front Pediatr*.
642 2021;9:630817.
- 643 [51] Jin L, Yu B, Armando I, et al. Mitochondrial DNA-Mediated Inflammation in Acute Kidney
644 Injury and Chronic Kidney Disease. *Oxidative Medicine and Cellular Longevity*. 2021
645 2021/06/30;2021:9985603.
- 646 [52] Tan K, Fujimoto M, Takii R, et al. Mitochondrial SSBP1 protects cells from proteotoxic
647 stresses by potentiating stress-induced HSF1 transcriptional activity. *Nat Commun*. 2015
648 Mar 12;6:6580.
- 649 [53] Ferat-Osorio E, Sánchez-Anaya A, Gutiérrez-Mendoza M, et al. Heat shock protein 70
650 down-regulates the production of toll-like receptor-induced pro-inflammatory cytokines

- 651 by a heat shock factor-1/constitutive heat shock element-binding factor-dependent
652 mechanism. *Journal of Inflammation*. 2014 2014/07/12;11(1):19.
- 653 [54] Afrazi A, Sodhi CP, Good M, et al. Intracellular heat shock protein-70 negatively
654 regulates TLR4 signaling in the newborn intestinal epithelium. *J Immunol*. 2012 May
655 1;188(9):4543-57.
- 656 [55] Ross D, Siegel D. Functions of NQO1 in Cellular Protection and CoQ10 Metabolism and
657 its Potential Role as a Redox Sensitive Molecular Switch [Review]. *Frontiers in*
658 *Physiology*. 2017 2017-August-24;8.
- 659 [56] Zhang Y, Wang O, Mi H, et al. *Rhus chinensis* Mill. fruits prevent necrotizing enterocolitis
660 in rat pups via regulating the expressions of key proteins involved in multiple signaling
661 pathways. *J Ethnopharmacol*. 2022 May 23;290:115103.
- 662 [57] Wohlschlegel J, Argentini M, Michiels C, et al. First identification of ITM2B interactome in
663 the human retina. *Scientific Reports*. 2021 2021/08/26;11(1):17210.
- 664 [58] Yuan Z-C, Xu W-D, Liu X-Y, et al. Biology of IL-36 Signaling and Its Role in Systemic
665 Inflammatory Diseases [Review]. *Frontiers in Immunology*. 2019 2019-October-31;10.
- 666 [59] Carrier Y, Ma H-L, Ramon HE, et al. Inter-Regulation of Th17 Cytokines and the IL-36
667 Cytokines In Vitro and In Vivo: Implications in Psoriasis Pathogenesis. *Journal of*
668 *Investigative Dermatology*. 2011 2011/12/01;131(12):2428-2437.
- 669 [60] Cho SX, Rudloff I, Lao JC, et al. Characterization of the pathoimmunology of necrotizing
670 enterocolitis reveals novel therapeutic opportunities. *Nat Commun*. 2020 Nov
671 13;11(1):5794.
- 672 [61] Sekikawa A, Fukui H, Suzuki K, et al. Involvement of the IL-22/REG α axis in
673 ulcerative colitis. *Lab Invest*. 2010 Mar;90(3):496-505.
- 674 [62] He GW, Lin L, DeMartino J, et al. Optimized human intestinal organoid model reveals
675 interleukin-22-dependency of paneth cell formation. *Cell Stem Cell*. 2022 Sep
676 1;29(9):1333-1345.e6.
- 677 [63] Nguyen PM, Putoczki TL, Ernst M. STAT3-Activating Cytokines: A Therapeutic
678 Opportunity for Inflammatory Bowel Disease? *J Interferon Cytokine Res*. 2015
679 May;35(5):340-50.
- 680 [64] Ma Q, Luan J, Bai Y, et al. Interleukin-22 in Renal Protection and Its Pathological Role in
681 Kidney Diseases. *Front Immunol*. 2022;13:851818.
- 682 [65] Rushworth SA, MacEwan DJ, O'Connell MA. Lipopolysaccharide-induced expression of
683 NAD(P)H:quinone oxidoreductase 1 and heme oxygenase-1 protects against excessive
684 inflammatory responses in human monocytes. *J Immunol*. 2008 Nov 15;181(10):6730-7.
- 685 [66] Esmon CT. The impact of the inflammatory response on coagulation. *Thrombosis*
686 *Research*. 2004 2004/01/01;114(5):321-327.
- 687 [67] Mao H, Han B, Li H, et al. FABP4 knockdown suppresses inflammation, apoptosis and
688 extracellular matrix degradation in IL-1 β -induced chondrocytes by activating PPAR γ to
689 regulate the NF- κ B signaling pathway. *Mol Med Rep*. 2021 2021/12/01;24(6):855.
- 690 [68] de Leeuw E, Rajabi M, Zou G, et al. Selective arginines are important for the
691 antibacterial activity and host cell interaction of human alpha-defensin 5. *FEBS Lett*.
692 2009 Aug 6;583(15):2507-12.
- 693 [69] Schurink M, Scholten IG, Kooi EM, et al. Intestinal fatty acid-binding protein in neonates
694 with imminent necrotizing enterocolitis. *Neonatology*. 2014;106(1):49-54.
- 695 [70] Coufal S, Kokesova A, Tlaskalova-Hogenova H, et al. Urinary I-FABP, L-FABP, TFF-3,
696 and SAA Can Diagnose and Predict the Disease Course in Necrotizing Enterocolitis at

- 697 the Early Stage of Disease. *Journal of Immunology Research*. 2020
698 2020/03/03;2020:3074313.
- 699 [71] Chen CC, Llado V, Eurich K, et al. Carbohydrate-binding motif in chitinase 3-like 1
700 (CHI3L1/YKL-40) specifically activates Akt signaling pathway in colonic epithelial cells.
701 *Clin Immunol*. 2011 Sep;140(3):268-75.
- 702 [72] Schlapbach LJ, Aebi C, Fisch U, et al. Higher Cord Blood Levels of Mannose-Binding
703 Lectin-Associated Serine Protease-2 in Infants With Necrotising Enterocolitis. *Pediatric
704 Research*. 2008 2008/11/01;64(5):562-566.
- 705 [73] Sylvester KG, Ling XB, Liu GY, et al. Urine protein biomarkers for the diagnosis and
706 prognosis of necrotizing enterocolitis in infants. *J Pediatr*. 2014 Mar;164(3):607-12 e1-7.
- 707 [74] Visscher MO, Carr AN, Narendran V. Epidermal Immunity and Function: Origin in
708 Neonatal Skin [Review]. *Frontiers in Molecular Biosciences*. 2022 2022-June-08;9.
- 709 [75] Chau S, Gao J, Diao AJ, et al. Diverse yeast antiviral systems prevent lethal
710 pathogenesis caused by the L-A mycovirus. *Proceedings of the National Academy of
711 Sciences*. 2023;120(11):e2208695120.
- 712 [76] Fehr AR, Singh SA, Kerr CM, et al. The impact of PARPs and ADP-ribosylation on
713 inflammation and host-pathogen interactions. *Genes Dev*. 2020 Mar 1;34(5-6):341-359.
- 714 [77] Williams D, Mahmoud M, Liu R, et al. Stable flow-induced expression of KLK10 inhibits
715 endothelial inflammation and atherosclerosis. *eLife*. 2022 2022/01/11;11:e72579.
- 716 [78] Czyzyk J, Henegariu O, Preston-Hurlburt P, et al. Enhanced Anti-Serpin Antibody Activity
717 Inhibits Autoimmune Inflammation in Type 1 Diabetes. *The Journal of Immunology*.
718 2012;188(12):6319-6327.
- 719 [79] Chamberlain PP, Qian X, Stiles AR, et al. Integration of inositol phosphate signaling
720 pathways via human ITPK1. *J Biol Chem*. 2007 Sep 21;282(38):28117-25.
- 721 [80] Luke CJ, Pak SC, Askew YS, et al. An intracellular serpin regulates necrosis by inhibiting
722 the induction and sequelae of lysosomal injury. *Cell*. 2007 Sep 21;130(6):1108-19.
- 723 [81] Lee YJ, Park SY, Park EK, et al. Unique cartilage matrix-associated protein regulates
724 fibrillin-2 expression and directly interacts with fibrillin-2 protein independent of calcium
725 binding. *Biochem Biophys Res Commun*. 2019 Apr 2;511(2):221-227.
- 726 [82] Lee SR, Heo JH, Jo SL, et al. Progesterone receptor membrane component 1 reduces
727 cardiac steatosis and lipotoxicity via activation of fatty acid oxidation and mitochondrial
728 respiration. *Sci Rep*. 2021 Apr 22;11(1):8781.
- 729 [83] Luo K, Zhang L, Liao Y, et al. Effects and mechanisms of Eps8 on the biological
730 behaviour of malignant tumours (Review). *Oncol Rep*. 2021 2021/03/01;45(3):824-834.
- 731 [84] Pan W, Nagpal K, Suárez-Fueyo A, et al. The Regulatory Subunit PPP2R2A of PP2A
732 Enhances Th1 and Th17 Differentiation through Activation of the GEF-H1/RhoA/ROCK
733 Signaling Pathway. *J Immunol*. 2021 Apr 15;206(8):1719-1728.
- 734 [85] Kerr SC, Fieger CB, Snapp KR, et al. Endoglycan, a member of the CD34 family of
735 sialomucins, is a ligand for the vascular selectins. *J Immunol*. 2008 Jul 15;181(2):1480-
736 90.
- 737 [86] Zhu C, Liu C, Chai Z. Role of the PADI family in inflammatory autoimmune diseases and
738 cancers: A systematic review. *Front Immunol*. 2023;14:1115794.
- 739 [87] Abbasoglu A, Sarialioglu F, Yazici N, et al. Serum Neuron-specific Enolase Levels in
740 Preterm and Term Newborns and in Infants 1–3 Months of Age. *Pediatrics &
741 Neonatology*. 2015 2015/04/01;56(2):114-119.

- 742 [88] Lin SN, Musso A, Wang J, et al. Human intestinal myofibroblasts deposited collagen VI
743 enhances adhesiveness for T cells - A novel mechanism for maintenance of intestinal
744 inflammation. *Matrix Biol.* 2022 Nov;113:1-21.
- 745 [89] Lin H, Zeng W, Lei Y, et al. Tuffelin 1 (TUFT1) Promotes the Proliferation and Migration
746 of Renal Cell Carcinoma via PI3K/AKT Signaling Pathway. *Pathol Oncol Res.*
747 2021;27:640936.
- 748 [90] Grover R, Burse SA, Shankrit S, et al. Myg1 exonuclease couples the nuclear and
749 mitochondrial translational programs through RNA processing. *Nucleic Acids Res.* 2019
750 Jun 20;47(11):5852-5866.
- 751 [91] Ma J, Wei K, Liu J, et al. Glycogen metabolism regulates macrophage-mediated acute
752 inflammatory responses. *Nat Commun.* 2020 Apr 14;11(1):1769.
- 753 [92] Koyama S, Akbay EA, Li YY, et al. STK11/LKB1 Deficiency Promotes Neutrophil
754 Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the
755 Lung Tumor Microenvironment. *Cancer Res.* 2016 Mar 1;76(5):999-1008.
- 756 [93] Sodhi CP, Shi XH, Richardson WM, et al. Toll-like receptor-4 inhibits enterocyte
757 proliferation via impaired beta-catenin signaling in necrotizing enterocolitis.
758 *Gastroenterology.* 2010 Jan;138(1):185-96.

759

760

761

Table 1. Study cohort characteristics

Sample ID		Pregnancy and delivery details				Disease severity		Surgical intervention		
Sample ID	NEC/ Control	Gestational age range (weeks)	Biological sex	Birth weight (g)	Route of delivery	NEC	Highest Bell's stage	Radiologic Findings	Surgical NEC	Final disposition
Age-Matched										
AM 1	N	23 - 27	Male	480	CS	Yes	IIB	PN		Death, LD
AM 1	C	33 - 37	Female	1940	V	No				Discharged
AM 2	N	33 - 37	Female	2360	CS	Yes	IIA	PN		Discharged
AM 2	C	33 - 37	Female	1740	CS	No				Discharged
AM 3	N	33 - 37	Female	2330	CS	Yes	IIB	PN, PVG		Discharged
AM 3	C	33 - 37	Male	2360	CS	No				Discharged
AM 4	N	23 - 27	Male	640	CS	Yes	IIB	PN		Discharged
AM 4	C	23 - 27	Female	710	CS	No				Discharged
AM 5	N	28 - 32	Female	1190	CS	Yes	IIB	PN, PVG		Discharged
AM 5	C	33 - 37	Male	2030	V	No				Discharged
AM 6	N	23 - 27	Male	700	CS	Yes	IIIB	G	PR, PD	Death, LD
AM 6	C	23 - 27	Male	1150	V	No				Discharged
AM 7	N	28 - 32	Female	1870	CS	Yes	IIA	PN		Discharged
AM 7	C	28 - 32	Female	2320	V	No				Discharged
AM 8	N	23 - 27	Female	790	V	Yes	IIB	PN		Discharged
AM 8	C	28 - 32	Male	1580	V	No				Discharged
Self-Matched										
SM 9	C+N	28 - 32	Male	1220	CS	Yes	IIIA	PN, PVG		Discharged
SM10	C+N	23 - 27	Female	760	V	Yes	IIIB	PN, PVG, P	PD	Death, NEC
SM11	C+N	23 - 27	Male	760	CS	Yes	IIA	PN		Discharged
SM12	C+N	23 - 27	Male	790	CS	Yes	IIIB	P	PR	Discharged
SM13	C+N	28 - 32	Female	1775	V	Yes	IB			Discharged
SM14	C+N	28 - 32	Male	1780	CS	Yes	IIB	PN		Discharged
SM15	C+N	23 - 27	Female	690	CS	Yes	II			Study closed
SM16	C+N	23 - 27	Male	430	CS	Yes	IIB	PN		Death, LD
SM17	C+N	28 - 32	Male	1770	CS	Yes	IIB	PN		Discharged
SM18	C+N	23 - 27	Female	710	CS	Yes	IIA	PN		Discharged
SM19	C+N	23 - 27	Male	530	CS	Yes	IIIA	G		Death, LD
SM20	C+N	23 - 27	Male	660	CS	Yes	IIIB	PVG	PR	Study closed

Delivery route: CS = cesarean Section, V = vaginal; Surgical NEC: PR = partial resection, PD = peritoneal drain; Disposition: LD = lung disease, Radiological findings: PN = pneumatosis, PVG = portal venous gas, P = pneumoperitoneum, G = gasless abdomen, Study closed = PI relocation.

Table 2. Classification of differentially abundant urine proteins identified by the SomaScan® (7K) assay.

Protein name			Enrichment		Protein Function		Accuracy	REF
Entrez Gene Symbol	UniProt ID	Median fold change	Consensus tissue enrichment	Consensus localization enrichment	Role in inflammation ▲ Anti-microbial, ■ Non-specific inflammation, ◆ Intestinal inflammation, ● Associated with NEC, ☆ Putative marker for NEC		AUC 95% CI	
Increased								
REG1B	P48304	9.2	Intestine, pancreas	Secreted locally	▲●☆	Putative antimicrobial properties. Regulated by STAT3. Upregulated in NEC.	0.82 (0.69-0.95)	[36]
SSBP1	Q04837	5.7	Ubiquitous	Mitochondrial	■	Critical regulator in mitochondrial DNA maintenance. Protects cells against proteotoxic stress	0.83 (0.70-0.96)	[52]
CRYZL1	O95825	3.7	Ubiquitous	Intracellular	■	Lipopolysaccharide (LPS)-induced expression mitigates pro-inflammatory responses in human monocytes.	0.76 (0.59-0.92)	[65]
F9	P00740	3.2	Liver	Secreted to blood	■	An inflammatory response factor involved in the intrinsic blood coagulation pathway by activating factor X.	0.67 (0.50-0.84)	[66]
FABP4	P15090	3.0	Adipocyte	Intracellular	■	Promotes inflammation. Downregulation suppresses inflammation, apoptosis, and oxidative stress.	0.69 (0.52-0.85)	[67]
HAMP	P81172	3.0	Liver	Secreted to blood	▲■	Anti-microbial activity and anti-inflammatory IL-6 mediated-iron sequestering response.	0.76 (0.61-0.91)	[46]
DEFA5	Q01523	3.0	Intestine	Locally secreted	▲●☆	Paneth cell anti-microbial peptide. Induces secretion of IL-8 by intestinal epithelial cells. Increased in NEC.	0.66 (0.49-0.83)	[68]
FABP2	P12104	3.0	Intestine	Intracellular	●☆	Intestinal fatty acid binding protein. Putative biomarker which correlates with NEC in urine and serum.	0.68 (0.51-0.84)	[69]
FABP1	P07148	2.8	Liver, intestine	Intracellular	◆●	Liver fatty acid binding protein. Putative urine marker for NEC in urine.	0.63 (0.45-0.80)	[70]
CHI3L1	P36222	2.8	Macrophages	Secreted to blood	◆	Pro-inflammatory signaling in colitis by AKT, TNF α , and IL-8. A putative marker for intestinal inflammation.	0.71 (0.55-0.87)	[71]
REG3A	Q06141	2.6	Intestine	Secreted locally	▲◆●	Increased transcription observed in NEC. Antimicrobial peptide. Regulated by IL-17.	0.79 (0.65-0.93)	[49]
C2	P06681	2.6	Liver	Secreted to blood		MASP-2, an enzyme that regulates C2 and C4 activity, is associated with the development of NEC.	0.65 (0.48-0.82)	[72]
Decreased								
ITM2B	Q9Y287	-9.8	Ubiquitous	Membrane	■	Regulates anti-microbial amyloid-beta peptide aggregation.	0.79 (0.65-0.94)	[57]
A2ML1	A8K2U0	-7.0	Squamous epithelium	Secreted locally	☆	Inactivates digestive proteases by covalent binding. Putative urine marker to distinguish NEC severity.	0.74 (0.59-0.89)	[73]
IL36B	Q9NZH7	-6.1	Keratinocyte,	Secreted locally	■	A pro-inflammatory cytokine that triggers MAPK and NF- κ B signaling pathways.	0.86 (0.75-0.98)	[58]
TGM3	Q08188	-4.3	Squamous epithelium	Secreted to blood	●	Involved in innate immunity and barrier integrity.	0.71 (0.54-0.87)	[74]
REXO2	Q9Y3B8	-3.7	Mitochondrial	Intracellular	▲	A putative anti-viral exoribonuclease that preferentially degrades two nucleotide RNA and DNA.	0.78 (0.63-0.92)	[75]
ADPRS	Q9NX46	-3.7	Ubiquitous	Intracellular		Post-translational modification of ribose to proteins, ribosylation linked to immune response modulation.	0.70 (0.54-0.87)	[76]
KLK10	O43240	-3.5	Ubiquitous	Secreted locally	■	Serine protease which can inhibit endothelial inflammation in blood vessels.	0.75 (0.60-0.90)	[77]
SERPINB13	Q9UIV8	-3.2	Squamous epithelium	Intracellular		Anti-inflammatory serine protease inhibitor.	0.65 (0.48-0.82)	[78]
ITPK1	Q13572	-3.0	Ubiquitous	Mitochondrial	■	Protects against TNF α -induced apoptosis and MLKL-mediated necroptosis.	0.81 (0.65-0.96)	[79]
SERPINB3	P29508	-3.0	Squamous epithelium	Intracellular	■	Cysteine protease inhibitor. Modulates immune response and regulates necrosis.	0.72 (0.55-0.88)	[80]
UCMA	Q8WVF2	-3.0	Chondrocytes	Extracellular matrix		A secretory γ -carboxyglutamate that regulates fibrillin 2.	0.65 (0.48-0.82)	[81]
PGRMC1	O00264	-3.0	Ubiquitous	Membrane, Mitochondrial		Reduces lipotoxicity through fatty acid oxidation and mitochondrial respiration.	0.72 (0.55-0.88)	[82]
EPS8L2	Q9H6S3	-2.8	Ubiquitous	Intracellular		An analog of the EGFR receptor substrate has unknown involvement in the actin cytoskeleton remodeling.	0.83 (0.70-0.96)	[83]
PPP1R2	P41236	-2.8	Ubiquitous	Intracellular	■	Enhances Th17 differentiation and regulates TLR/ NF- κ B , and MAPK signaling.	0.79 (0.65-0.93)	[84]
PODXL2	Q9NZ53	-2.8	Ubiquitous	Intracellular	■	Mediates leukocyte migration by acting as a ligand for vascular selectins E-, P-, and L-selectins.	0.73 (0.57-0.90)	[85]
PADI1	Q9ULC6	-2.8	Keratinocytes	Intracellular	■	Involved in the differentiation of immune cells. Regulated by NF- κ B .	0.64 (0.47-0.81)	[86]
IL36RN	Q9UBH0	-2.6	Keratinocytes	Intracellular	■	Antagonist of the IL-36 signaling in epithelial barriers. High IL-36:IL36RN ratios observed in NEC.	0.91 (0.82-0.99)	[60]
ENO2	P09104	-2.6	CNS and pancreas	Intracellular		Gamma enolase is the predominant CNS dimer. Elevated in serum of preterm infants.	0.78 (0.63-0.92)	[87]
COL6A1	P12109	-2.6	Connective tissue	Extracellular matrix	■	Myofibroblasts deposit collagen VI to enhance T-cell adhesion to regulate intestinal inflammation.	0.73 (0.57-0.89)	[88]
TUFT1	Q9NNX1	-2.6	Ubiquitous	Secreted locally		Involved in mesenchymal stem cell function and adaptation to hypoxia.	0.73 (0.57-0.89)	[89]
MYG1	Q9HB07	-2.6	Ubiquitous	Intracellular		Exonuclease which cleaves in situ at specific transcripts.	0.71 (0.55-0.88)	[90]
PYGL	P06737	-2.6	Ubiquitous, liver	Intracellular	■	Strongly linked to inflammation through glycogen metabolism	0.70 (0.54-0.87)	[91]
CAB39	Q9Y376	-2.6	Ubiquitous	Intracellular		Component of a complex that binds and activates STK11/LKB1 (tumor suppressor).	0.70 (0.53-0.86)	[92]
CTNBP1	Q9NSA3	-2.6	Ubiquitous	Intracellular	●	Enterocyte proliferation is impaired by dampened WNT/beta-catenin signaling in NEC.	0.67 (0.50-0.83)	[93]

Table 3. Ingenuity pathway upstream regulator analysis

Causal Network Analysis							
Master Regulator	Protein Name	UniProt	Molecule Type	Predicted Activation	Activation z-score	P-value of overlap	Network bias-corrected P-value
TNFRSF1B	TNF receptor-associated factor 2	Q12933	Transmembrane receptor	Activated	2.353	1.0E-09	0.0003
ZFP36	mRNA decay activator protein ZFP36	P26651	Transcription regulator	Activated	2.263	7.4E-07	0.0153
ZC3H12A	Endoribonuclease ZC3H12A	Q5D1E8	Enzyme	Activated	2.191	1.7E-05	0.0430
IL22	Interleukin-22	Q9GZX6	Cytokine	Activated	2.000	6.9E-04	0.0171
USP11	Ubiquitin carboxyl-terminal hydrolase 11	P51784	Peptidase	Inhibited	-2.121	9.6E-07	0.0140
EML4-ALK	Tyrosine-protein kinase receptor	J7MA22	Fusion gene/product	Inhibited	-2.137	2.9E-08	0.0018
ALDH1A3	Aldehyde dehydrogenase family 1 member A3	P47895	Enzyme	Inhibited	-2.236	8.0E-06	0.0005
GRM1	Metabotropic glutamate receptor 1	Q13255	G-protein coupled receptor	Inhibited	-2.263	1.8E-05	0.0263
PLCE1	1-phosphatidylinositol 4,5-bisphosphatesphodiesterase E1	Q9P212	Enzyme	Inhibited	-2.401	6.4E-06	0.0274
RNF11	RING finger protein 11	Q9Y3C5	Enzyme	Inhibited	-2.414	4.3E-06	0.0435
SEPTIN9	Septin-9	Q9UHD8	Enzyme	Inhibited	-2.502	7.3E-06	0.0178
Upstream Regulator analysis							
Upstream Regulator	Protein name	UniProt	Molecule Type	Predicted Activation	Activation z-score	P-value of overlap	
Esrra	Steroid hormone receptor ERR1	P11474	Ligand-dependent nuclear	Activated	2.000	0.0003	
IL22	Interleukin-22	Q9GZX6	Cytokine		1.957	0.0009	
SREBF1	Sterol regulatory element-binding protein 1	P36956	Transcription regulator		1.950	0.0001	
RXRA	Retinoic acid receptor RXR-alpha	P19793	Ligand-dependent nuclear		1.941	0.0079	
PGR	Progesterone receptor	P06401	Ligand-dependent nuclear		1.732	0.0499	
STAT3	Signal transducer and activator of transcription 3	P40763	Transcription regulator		0.736	0.0000	
HIF1A	Hypoxia-inducible factor 1-alpha	Q16665	Transcription regulator	Inhibited	-2.177	0.0013	
TNF	Tumor necrosis factor	P01375	Cytokine	Inhibited	-2.130	0.0026	
KLF6	Kruppel-like factor 6	Q99612	Transcription regulator	Inhibited	-2.000	0.0078	
TGFB1	Transforming growth factor beta-1 proprotein	P01137	Growth factor		-1.338	0.0018	
IL1B	Interleukin-1 beta	P01584	Cytokine		-1.277	0.0001	
NFE2L2	Nuclear factor erythroid 2-related factor 2	Q16236	Transcription regulator		-1.233	0.0198	
IL10RA	Interleukin-10 receptor subunit alpha	Q13651	Transmembrane receptor		-1.000	0.0123	
LPS	lipopolysaccharide		Chemical drug		-0.942	0.0000	
CTNNB1	Catenin beta-1	P35222	Transcription regulator		-0.686	0.0026	
TGM2	Protein-glutamine gamma-glutamyltransferase 2	P21980	Enzyme		-0.664	0.0005	
AHR	Aryl hydrocarbon receptor	P35869	Ligand-dependent nuclear		-0.517	0.0001	

Graphical abstract




Figure 1






Figure 2



B Protein Panel 1



C Protein Panel 2




Figure 3




Figure 4




Figure 5




Figure 6

